XML 29 R19.htm IDEA: XBRL DOCUMENT v3.6.0.2
Segment Information (Tables)
 9 Months Ended
Jan. 31, 2017
Segment Reporting [Abstract]  
Summary of Segment Activity
The following tables summarize, for the periods indicated, operating results by reportable segment (table in thousands):
Three months ended January 31, 2017
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
347

 
$
3,218

 
$
—

 
$
3,565

Direct cost of services
 
(320
)
 
(2,084
)
 
—

 
(2,404
)
Sales and marketing costs
 
(128
)
 
(591
)
 
—

 
(719
)
Other operating expenses
 
—

 
(953
)
 
(653
)
 
(1,606
)
Stock- based compensation expense (1)
 
—

 
—

 
(237
)
 
(237
)
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(101
)
 
$
(410
)
 
$
(890
)
 
$
(1,401
)
 
Three months ended January 31, 2016
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
416

 
$
2,136

 
$
—

 
$
2,552

Direct cost of services
 
(479
)
 
(1,624
)
 
—

 
(2,103
)
Sales and marketing costs
 
(183
)
 
(569
)
 
—

 
(752
)
Other operating expenses
 
—

 
(950
)
 
(553
)
 
(1,503
)
Stock- based compensation expense (1)
 
—

 
—

 
(567
)
 
(567
)
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(246
)
 
$
(1,007
)
 
$
(1,120
)
 
$
(2,373
)
 
Nine Months Ended January 31, 2017
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
1,354

 
$
10,337

 
$
—

 
$
11,691

Direct cost of services
 
(1,165
)
 
(5,916
)
 
—

 
(7,081
)
Sales and marketing costs
 
(397
)
 
(1,778
)
 
—

 
(2,175
)
Other operating expenses
 
—

 
(3,043
)
 
(1,911
)
 
(4,954
)
Stock- based compensation expense (1)
 
—

 
—

 
(1,901
)
 
(1,901
)
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(208
)
 
$
(400
)
 
$
(3,812
)
 
$
(4,420
)
 
Nine Months Ended January 31, 2016
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
1,387

 
$
6,958

 
$
—

 
$
8,345

Direct cost of services
 
(1,634
)
 
(4,654
)
 
—

 
(6,288
)
Sales and marketing costs
 
(716
)
 
(1,800
)
 
—

 
(2,516
)
Other operating expenses
 
—

 
(2,755
)
 
(2,463
)
 
(5,218
)
Stock- based compensation expense (1)
 
—

 
—

 
(2,090
)
 
(2,090
)
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(963
)
 
$
(2,251
)
 
$
(4,553
)
 
$
(7,767
)

(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments. See Note 3 for the allocation of stock compensation expense relative to the individual line items as it is reported on the Company's Consolidated Statements of Operations.